Evidence map›Paper›PMID 41366132›Full record

ArticleProstate cancer and prostatic diseases2026

Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.

Anita Csizmarik, Nikolett Nagy, Dávid Keresztes, Melinda Váradi, Thilo Bracht, Barbara Sitek, Kathrin Witzke, Martin Puhr, Ilona Tornyi, József Lázár and 7 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Anita Csizmarik *Department of Urology, Semmelweis University, Budapest, Hungary.
Nikolett Nagy *Department of Urology, Semmelweis University, Budapest, Hungary.
Dávid KeresztesDepartment of Urology, Semmelweis University, Budapest, Hungary.
Melinda VáradiDepartment of Urology, Semmelweis University, Budapest, Hungary.
Thilo BrachtMedizinisches Proteom-Center, Ruhr University Bochum, Bochum, Germany.
Barbara SitekMedizinisches Proteom-Center, Ruhr University Bochum, Bochum, Germany.
Kathrin WitzkeMedizinisches Proteom-Center, Ruhr University Bochum, Bochum, Germany.ORCID http://orcid.org/0000-0002-0662-3394
Martin PuhrDepartment of Urology, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0002-3858-9653
Ilona TornyiDepartment of Human Genetics, University of Debrecen, Debrecen, Hungary.ORCID http://orcid.org/0000-0003-2165-4196
József LázárDepartment of Human Genetics, University of Debrecen, Debrecen, Hungary.
László TakácsDepartment of Human Genetics, University of Debrecen, Debrecen, Hungary.
Gero KramerDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Sabina SevcencoDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Agnieszka Maj-HesDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Boris HadaschikDepartment of Urology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Péter NyirádyDepartment of Urology, Semmelweis University, Budapest, Hungary.
Tibor SzarvasDepartment of Urology, Semmelweis University, Budapest, Hungary. szarvas.tibor@med.semmelweis-univ.hu.ORCID http://orcid.org/0000-0002-6321-0799

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41366132
PMCPMC13472983

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.